For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

NRG BR004

Trial Overview

Official Title

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Study Purpose

To study how well paclitaxel, trastuzumab and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body. (metastatic)

Diagnosis

Locally recurrent, unresectable or metastatic breast cancer

Eligibility

HER2 positive breast cancer

Patients must sign an approved informed consent and authorization 

Intervention

  • Group 1: Paclitaxel, trastuzumab, pertuzumab, and placebo
  • Group 2: Paclitaxel, trastuzumab, pertuzumab, and atezolizumab

For more information, visit ClinicalTrials.gov 

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Phase
Phase III
Methodist Health System Trial Code
NRG BR004
Related Specialties